|
Q4 2023
|
102 |
416,585 |
AL, ENSG, CDNA, ISRG
|
13F-HR
|
2/14/2024 |
000101905624000095 |
|
Q3 2023
|
97 |
399,063 |
AL, ENSG, ISRG, NVGS
|
13F-HR
|
11/14/2023 |
000101905623000396 |
|
Q2 2023
|
97 |
480,938 |
AL, ENSG, ISRG, PCRX
|
13F-HR
|
8/8/2023 |
000101905623000328 |
|
Q1 2023
|
112 |
475,804 |
AL, ENSG, NVGS, PCRX
|
13F-HR
|
4/10/2023 |
000101905623000201 |
|
Q4 2022
|
106 |
452,942 |
AL, ENSG, PCRX, NVGS
|
13F-HR
|
2/7/2023 |
000101905623000104 |
|
Q3 2022
|
101 |
454,820 |
PCRX, AL, ENSG, CDNA
|
13F-HR
|
11/14/2022 |
000101905622000644 |
|
Q2 2022
|
101 |
477,076 |
PCRX, AL, ENSG, NVGS
|
13F-HR
|
8/1/2022 |
000101905622000526 |
|
Q1 2022
|
103 |
613,179 |
PCRX, AL, CDNA, ENSG
|
13F-HR
|
5/9/2022 |
000101905622000377 |
|
Q4 2021
|
105 |
666,799 |
AL, AOSL, CDNA, PCRX
|
13F-HR
|
2/8/2022 |
000101905622000153 |
|
Q3 2021
|
112 |
673,112 |
CDNA, AL, PCRX, ENSG
|
13F-HR
|
11/12/2021 |
000101905621000591 |
|
Q2 2021
|
111 |
704,320 |
CDNA, AL, ENSG, AMRC
|
13F-HR
|
7/28/2021 |
000101905621000437 |
|
Q1 2021
|
108 |
656,701 |
CDNA, AL, ENSG, PCRX
|
13F-HR
|
5/14/2021 |
000101905621000301 |
|
Q4 2020
|
99 |
628,130 |
CDNA, AL, AMRC, ENSG
|
13F-HR
|
2/12/2021 |
000101905621000108 |
|
Q3 2020
|
100 |
468,978 |
CDNA, AL, PCRX, ENSG
|
13F-HR
|
11/12/2020 |
000101905620000563 |
|
Q2 2020
|
91 |
412,965 |
CDNA, AL, PCRX, AMRC
|
13F-HR
|
8/13/2020 |
000101905620000474 |
|
Q1 2020
|
96 |
294,330 |
CDNA, AL, ENSG, AMRC
|
13F-HR
|
5/11/2020 |
000101905620000313 |
|
Q4 2019
|
93 |
456,867 |
AL, GFN, CDNA, EVBG
|
13F-HR
|
2/14/2020 |
000101905620000156 |
|
Q3 2019
|
95 |
422,607 |
AL, CDNA, GFN, ENSG
|
13F-HR
|
11/8/2019 |
000101905619000636 |
|
Q2 2019
|
97 |
463,774 |
CDNA, AL, ENSG, EVBG
|
13F-HR
|
8/12/2019 |
000101905619000468 |
|
Q1 2019
|
97 |
458,671 |
CDNA, AL, ENSG, EVBG
|
13F-HR
|
5/13/2019 |
000101905619000286 |
|
Q4 2018
|
93 |
376,005 |
CDNA, AL, GFN, ENSG
|
13F-HR
|
1/18/2019 |
000101905619000021 |
|
Q3 2018
|
101 |
435,126 |
CDNA, GFN, AL, ENSG
|
13F-HR
|
11/13/2018 |
000101905618001065 |
|
Q2 2018
|
97 |
346,700 |
GFN, CDNA, AL, LL
|
13F-HR
|
8/9/2018 |
000101905618000942 |
|
Q1 2018
|
95 |
280,913 |
AL, RHT, GFN, CDNA
|
13F-HR
|
5/9/2018 |
000101905618000597 |
|
Q4 2017
|
91 |
281,801 |
AL, GFN, CDNA, RHT
|
13F-HR
|
2/13/2018 |
000101905618000332 |
|
Q3 2017
|
95 |
269,005 |
AL, RHT, LL, FIVN
|
RESTATEMENT
|
11/14/2017 |
000101905617000770 |
|
Q2 2017
|
89 |
360,479 |
RHT, AL, LL, FIVN
|
13F-HR
|
7/20/2017 |
000101905617000611 |
|
Q1 2017
|
95 |
231,181 |
AL, LL, RHT, ATHENAHEALTH INC
|
13F-HR
|
5/11/2017 |
000101905617000443 |
|
Q4 2016
|
96 |
233,147 |
AL, RTEC, GENERAL FINANCE CORPORATION, ATHENAHEALTH INC
|
13F-HR
|
2/14/2017 |
000101905617000184 |
|
Q3 2016
|
97 |
234,999 |
AL, ATHENAHEALTH INC, AMBR, RTEC
|
13F-HR
|
11/14/2016 |
000101905616001642 |
|
Q2 2016
|
92 |
214,357 |
ATHENAHEALTH INC, EQIX, AL, AMBR
|
RESTATEMENT
|
8/24/2016 |
000101905616001510 |
|
Q1 2016
|
88 |
208,884 |
AL, ATHENAHEALTH INC, EQIX, RHT
|
13F-HR
|
5/3/2016 |
000101905616001288 |
|
Q4 2015
|
86 |
218,359 |
ATHENAHEALTH INC, RHT, AL, EQIX
|
13F-HR
|
2/16/2016 |
000101905616001071 |
|
Q3 2015
|
88 |
204,427 |
RHT, EQIX, AL, ATHENAHEALTH INC
|
13F-HR
|
10/16/2015 |
000101905615000817 |
|
Q2 2015
|
89 |
252,756 |
AL, RHT, EQIX, NVCN
|
13F-HR
|
7/24/2015 |
000101905615000637 |
|
Q1 2015
|
93 |
301,431 |
AL, NVCN, GFN, RHT
|
13F-HR
|
5/12/2015 |
000101905615000478 |
|
Q4 2014
|
95 |
311,909 |
GFN, EQIX, RHT, CONSTANT CONTACT INC
|
13F-HR
|
2/13/2015 |
000101905615000174 |
|
Q3 2014
|
99 |
299,341 |
GFN, EQIX, AL, ATHENAHEALTH INC
|
13F-HR
|
10/15/2014 |
000101905614001315 |
|
Q2 2014
|
106 |
308,944 |
GFN, NVCN, AL, EQIX
|
13F-HR
|
7/31/2014 |
000101905614000976 |
|
Q1 2014
|
104 |
336,609 |
GFN, AL, ATHENAHEALTH INC, NVCN
|
13F-HR
|
5/6/2014 |
000101905614000638 |
|
Q4 2013
|
98 |
333,057 |
NOVADAQ TECHNOLOGIES INC COMMON, GFN, ATHENAHEALTH INC, AL
|
RESTATEMENT
|
2/6/2014 |
000101905614000137 |